NLRP3 and gout: Although no significant change in the expression of NLRP3 after supplementation with butyrate was observed in both the gout and peritonitis models, supplementation with butyrate effectively suppressed the production of caspase-1 and IL-1β (Figure 7j, Figure 7—figure supplement 1l).